TIGER-3: A phase 3, open-label, randomized study of rociletinib vs cytotoxic chemotherapy in patients (pts) with mutant EGFR non-small cell lung cancer (NSCLC) progressing on prior EGFR TKI therapy and doublet chemotherapy. Yang, J., Popat, S., Georgiou, P., Miyamoto, E., Isaacson, J. D., Wakelee, H. A. AMER SOC CLINICAL ONCOLOGY. 2015

View details for Web of Science ID 000358036904858